Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether PEG changes need for additional therapies compared with flixweed (very low certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether PEG changes need for additional therapies compared with dietary fibre (very low certainty).
1 finding from 1 review
Frequency of faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG may leads to lower need for additional therapies compared with lactulose (low certainty).
1 finding from 1 review
Successful disimpaction · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG may leads to lower successful disimpaction compared with lactulose (low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in adverse events compared with lactulose (moderate certainty).
1 finding from 1 review
Serious adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in serious adverse events compared with lactulose (low certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Successful disimpaction · patients aged 0 to 18 years with a diagnosis of functional constipation
PEG showed no clear difference in successful disimpaction compared with milk of magnesia (MOM) (low certainty).
1 finding from 1 review
All‐cause mortality Deaths during and after the treatment · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes all‐cause mortality Deaths during and after the treatment compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Liver morbidity · people with chronic hepatitis C
It is very uncertain whether peginterferon alpha‐2a changes liver‐related morbidity Number of events compared with peginterferon alpha‐2b (very low certainty).
1 finding from 1 review
Serious adverse events Number of events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
All other (non‐serious) adverse events · people with chronic hepatitis C
1 finding from 1 review
Quality of life SF 36 and CLDQ · people with chronic hepatitis C
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
Peginterferon alpha‐2a probably leads to higher sustained virological response Absence of viraemia 24 weeks after… compared with peginterferon alpha‐2b (moderate certainty).
1 finding from 1 review
All‐cause mortality or liver‐related morbidity · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
OR 1.14 [0.38, 3.42]
1789 participants
Low